Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment.

Clinical pharmacology in drug development - 1 Sept 2015

Shilbayeh Sireen A R, Sy Sherwin K B, Melhem Murad, Zmeili Rawan, Derendorf Hartmut

Abstract excerpt

The aim of this study was to evaluate whether genetic polymorphisms in CYP3A5 and ABCB1 are responsible for the interindividual variability observed in quetiapine pharmacokinetics. Pharmacokinetic data from a randomized crossover study evaluating 2 quetiapine 25 mg immediate-release tablets after single oral dose were used to develop a population pharmacokinetic model. The single nucleotide polymorphisms (SNPs)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Healthy Volunteers

Share to Jordan

Share to Monte Carlo Method

Share to Nonlinear Dynamics

Share to Pharmacogenomic Variants

Source

Identifiers

PMID: 27137148
DOI: 10.1002/cpdd.172

Genes

ABCB1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment.PMID 27137148Read ↗

The impact of CYP3A5*3 on oral quetiapine: A population pharmacokinetic model in Chinese bipolar disorder patients.Semantic proximity Read ↗

Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers.Semantic proximity Read ↗

MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers.Semantic proximity Read ↗

So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics.Semantic proximity Read ↗

Effect of CYP3A5*3 genotype on exposure and efficacy of quetiapine: A retrospective, cohort study.Semantic proximity Read ↗

Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects.Semantic proximity Read ↗

Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects.Semantic proximity Read ↗

Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine.Semantic proximity Read ↗

Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes.Semantic proximity Read ↗

ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.Semantic proximity Read ↗

Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure.Semantic proximity Read ↗

Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.